Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 25 JANUARY 2017

Hot Topics In Supply Chain Compliance

Ropes & Gray LLP
Ropes & Gray LLP
Contributor
Ropes & Gray LLP

Ropes & Gray LLP

Ropes & Gray is one of the world’s most respected law firms, with offices in key business and...

View firm profile
Explore more from Ropes & Gray LLP

Each company will need to tailor its statement to its particular risk assessment and compliance program.

GlobalCorporate/Commercial Law
Michael Littenberg
Michael Littenberg
Author LinkedIn connections

The last few years have seen a proliferation of new supply chain-focused regulations and other compliance obligations, a trend which isn't likely to abate any time soon. In this Alert, we provide an overview of selected supply chain compliance items that should be on the radar screen of healthcare industry legal and compliance professionals in 2017.

Anti-Human Trafficking

Anti-human trafficking compliance is a newer area of focus for many healthcare companies as a result of recently adopted disclosure and compliance requirements and increasing stakeholder scrutiny.

The UK Modern Slavery Act (MSA). Starting this year, the MSA will require a significant number of healthcare companies to annually publish on their websites a statement describing the steps that they have taken during the preceding fiscal year to ensure that slavery and human trafficking are not taking place in any of their supply chains or in any part of their own businesses. This requirement applies

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP